ARK102 / ARKGENBioScions - LARVOL DELTA

ARK102, a novel tri-specific T cell engager targeting TROP2, HER2, and CD3 for treatment of solid tumors (AACR 2026) - "In vivo, ARK102 demonstrated robust, dose‑dependent antitumor activity in human PBMC‑reconstituted immunodeficient mice bearing HER2‑ and/or TROP2‑expressing tumor xenografts, without dose‑limiting toxicity at efficacious doses, and showed antitumor efficacy comparable to or greater than that of benchmark TROP2‑ADC and HER2‑ADC therapies.Together, these results highlight ARK102 as a potent and selective dual‑targeting T‑cell engager with the potential to expand treatment options for patients with solid tumors co‑expressing HER2 and TROP2. The compelling preclinical efficacy and favorable safety profile strongly support its further clinical evaluation."

Trispecific • Oncology • Solid Tumor • HER-2 • TACSTD2